#United States #New York #Kessler Topaz #Securities Fraud #uniQure

Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against uniQure N.V.

In recent news, Kessler Topaz Meltzer & Check, LLP has announced the filing of a securities fraud class action lawsuit against uniQure N.V., a biotechnology company listed on NASDAQ under the symbol QURE. This legal action is aimed at protecting the rights of investors who purchased uniQure ordinary shares during a specified period, which encompasses September 24, 2025, to October 31, 2025. The class action, titled Scocco v. uniQure N.V., has been lodged in the United States District Court for the Southern District of New York.

The Background of the Case

The allegations in the lawsuit arise from claims of material misstatements and omissions related to uniQure's development of gene therapies, specifically targeting Huntington's disease (HD). A key product in question is AMT-130, a gene therapy designed to address the progression of HD. Investors contend that uniQure misrepresented crucial details about the Phase I/II clinical trials for AMT-130 as well as the timeline for the company's Biologics License Application (BLA) submission to the FDA.

The complaint outlines that throughout the class period, the defendants made misleading statements regarding uniQure's operations and downplayed significant risks. It explicitly states that the study design for the pivotal research had not received full FDA approval, leading investors to believe in a significantly more positive and imminent approval outcome than was warranted.

Important Investor Deadlines

Investors affected by this alleged fraud have a critical deadline looming; they must file to seek lead plaintiff status in the case by April 13, 2026. This process allows an investor or a small group representing the class to lead the litigation on behalf of all affected parties. The court will typically appoint a lead plaintiff from those who demonstrate the largest financial interest in the case.

Kessler Topaz Meltzer & Check, LLP has extended an invitation to those who believe they may have lost money due to uniQure’s alleged misconduct, urging them to reach out. Eligible investors are encouraged to contact attorney Jonathan Naji, who offers no-cost case evaluations to discuss their legal options.

Next Steps for Affected Investors

Affected parties should not only consider seeking lead plaintiff status but also reach out to the law firm to discuss recovery options without any obligation. Investors can independently choose to secure their own legal counsel or to remain part of the class without active participation.

In light of these recent developments, investors need to stay informed about their rights and the potential for recovery related to their investments in uniQure N.V. Those wishing to engage further in this process should connect with Kessler Topaz Meltzer & Check, LLP for guidance.

About Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP is a renowned law firm specializing in plaintiff-side securities fraud lawsuits. The firm possesses a strong track record, having achieved substantial recoveries for investors in various class actions. With offices in both Pennsylvania and California, KTMC is uniquely positioned to represent individuals and institutions affected by securities violations. More information can be found by visiting their website at www.ktmc.com.

Investors are advised to act promptly to ensure their rights are protected during this critical time.